Skip to main content

Table 4 Adverse events

From: Apatinib treatment efficiently delays biochemical-only recurrent ovarian cancer progression

Adverse events Grades
1
(n, %)
2
(n, %)
3
(n, %)
4
(n, %)
Total
(n, %)
Hand-foot syndrome 5 (12.2%) 9 (22.0%) 5 (12.2%) 0 (0%) 19 (46.4%)
Mucositis 3 (7.3%) 6 (14.6%) 8 (19.5%) 0 (0%) 17 (41.5%)
Anorexia 12 (29.3%) 3 (7.3%) 1 (2.4%) 0 (0%) 16 (39.0%)
Fatigue 4 (9.8%) 7 (17.1%) 5 (12.2%) 0 (0%) 16 (39.0%)
Proteinuria 11 (26.8%) 4 (9.8%) 0 (0%) 0 (0%) 15 (36.6%)
Hypertension 5 (12.2%) 6 (14.6%) 3 (7.3%) 0 (0%) 14 (34.1%)
Pain 6 (14.6%) 4 (9.8%) 1 (2.4%) 0 (0%) 11 (26.8%)
Thrombocytopenia 6 (14.6%) 3 (7.3%) 2 (4.9%) 0 (0%) 11 (26.8%)
Neutropenia 2 (4.9%) 2 (4.9%) 1 (2.4%) 0 (0%) 5 (12.2%)
Transaminase increased 1 (2.4%) 3 (7.3%) 1 (2.4%) 0 (0%) 5 (12.2%)
Diarrhea 1 (2.4%) 2 (4.9%) 0 (0%) 0 (0%) 3 (7.3%)